GlassScriptPhysician profile
Katelyn A Meade
NPI 1518327121
$2,286.39
in general payments reported to CMS, 2019-2025
23 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $64.69 · 2021: $171 · 2022: $371 · 2023: $747 · 2024: $499 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,657 · Education: $23.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.55 |
| Education | $23.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $592.73 | 2021-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $427.24 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $361.93 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $282.83 | 2023-2025 | |
| Abbvie INC. | $119.02 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $114.85 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $44.96 | 2021 | |
| Phadia US INC. | $38.16 | 2022-2024 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.40 | 2023-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $24.73 | 2022 | |
| Astellas Pharma US INC | $23.62 | 2024 | Veozah |
| Shield Therapeutics INC | $22.77 | 2025 | |
| Halozyme INC | $22.13 | 2023 | |
| Nestle Healthcare Nutrition INC. | $21.81 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.89 | 2023 | Cuvitru |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $20.37 | 2023 | Arexvy |
| Viiv Healthcare Company | $19.97 | 2023 | Apretude |
| Abbott Laboratories | $19.00 | 2023 | Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $16.99 | 2020 | |
| Sanofi Pasteur INC. | $16.65 | 2023 | |
| Esperion Therapeutics, INC. | $14.48 | 2020 | |
| Exact Sciences Corporation | $13.53 | 2024 | Cologuard Collection Kit |
| Cleerly, INC. | $13.33 | 2024 | Cleerly Labs, Cleerly Ischemia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Meade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.